GSK Acquires Syndivia's Prostate Cancer ADC for £268m
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for prostate cancer treatment, despite having its own ADC in development for the same condition.
This move fuels the industry's growing interest in ADCs as a promising anti-tumour modality.
GSK is doubling down on the modality.
The acquisition combines business intelligence and editorial excellence to reach engaged professionals across leading media platforms.
Author's summary: GSK buys Syndivia's ADC for £268m.
More News
- How Johannesburg residents are protecting their power lines
- Tim Marshall on how geography still matters in modern wars
- Alleged Charlie Kirk assassin allowed to wear street clothes at trial
- Venture capital is not an asset class, says Sequoia's Roelof Botha | TechCrunch
- Feeling like a dog chasing his own tail in a country and a society out of control
- Venture Capital, Moonshots, and AI: The 2025 Tech Soap Opera